Atopix Therapeutics Limited is a clinical stage biotechnology company, wholly owned by Chiesi Farmaceutici, developing novel treatments for Th2-mediated eosinophilic asthma.
Atopix is developing a novel class of oral anti-Th2 therapies, called CRTH2 antagonists.
Our lead candidate, timapiprant, is currently being studied in a Phase 2 proof-of-concept study to evaluate the effect of timapiprant in patients with severe asthma who have persistent airway eosinophilia, despite treatment with high doses of inhaled corticosteroids; and a Phase 2a study of the response of asthmatics treated with timapiprant to rhinovirus infection (common cold).
Atopix’s drug programmes target the CRTH2 receptor which plays a pivotal role in the initiation and maintenance of allergic conditions. The company has a pipeline of small molecule drugs, the most advanced of which, timapiprant, is being assessed in three proof-of-concept clinical trials.
Timapiprant has demonstrated efficacy in both asthma and allergic rhinoconjunctivitis. Over 800 patients have been dosed to date and the drug has demonstrated an excellent safety profile.
Atopix drug development programmes are managed by an experienced team with a track-record of progressing drug programmes.